Contemporary treatment of metastatic renal cell carcinoma

  • Igor Stukalin Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
  • Nimira Alimohamed Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
  • Daniel Y.C. Heng | daniel.heng@albertahealthservices.ca Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.

Abstract

The introduction of targeted therapy has revolutionized the treatment of patients with metastatic renal cell carcinoma (mRCC). The current standard of care focuses on the inhibition of angiogenesis through the targeting of the vascular endothelial growth factor receptor (VEGFR) and the mammalian target of rapamycin (mTOR). Over the past few years, research exploring novel targeted agents has blossomed, leading to the approval of various targeted therapies. Furthermore, results from the CheckMate025 and the METEOR trials have brought about two additional novel options: the programmed cell death 1 (PD-1) checkpoint inhibitor nivolumab and the MET/VEGFR/AXL inhibitor cabozantinib, respectively. With the variety of therapeutic agents available for treatment of mRCC, research examining appropriate sequencing and combinations of the drugs is ongoing. This review discusses the role of prognostic criteria, such as those from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. It also covers the current standard of treatment for mRCC with targeted therapy in first-, second-, and thirdline setting. Additionally, the novel mechanism of action of nivolumab and cabozantinib, therapeutic sequencing and ongoing clinical trials are discussed.

Downloads

Download data is not yet available.

Author Biographies

Nimira Alimohamed, Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB

MD, Clinical Assistant Professor, University of Calgary Chair, Tom Baker Cancer Center

Daniel Y.C. Heng, Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB

MD, MPH, FRCPC

Clinical Associate Professor, University of Calgary Chair, Southern

Alberta GU Tumor Group Staff Medical Oncologist, Tom Baker Cancer Center

Published
2016-07-01
Section
Reviews
Keywords:
Renal cell carcinoma, targeted therapy, immunotherapy, nivolumab, cabozantinib.
Statistics
Abstract views: 2277

PDF: 1130
HTML: 1018
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Stukalin, I., Alimohamed, N., & Heng, D. (2016). Contemporary treatment of metastatic renal cell carcinoma. Oncology Reviews, 10(1). https://doi.org/10.4081/oncol.2016.295